Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients

Authors Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Tubie S, Khosla P

Published Date November 2013 Volume 2013:9 Pages 747—761


Received 18 July 2013, Accepted 10 October 2013, Published 28 November 2013

Zulfitri A Mat Daud,1 Boniface Tubie,2 Marina Sheyman,2 Robert Osia,2 Judy Adams,2 Sharon Tubie,2 Pramod Khosla1

1Department of Nutrition and Food Science, Wayne State University, Detroit, MI, USA; 2Great Lake Dialysis Clinic, LLC, Detroit, MI, USA

Purpose: Chronic hemodialysis patients experience accelerated atherosclerosis contributed to by dyslipidemia, inflammation, and an impaired antioxidant system. Vitamin E tocotrienols possess anti-inflammatory and antioxidant properties. However, the impact of dietary intervention with Vitamin E tocotrienols is unknown in this population.
Patients and methods: A randomized, double-blind, placebo-controlled, parallel trial was conducted in 81 patients undergoing chronic hemodialysis. Subjects were provided daily with capsules containing either vitamin E tocotrienol-rich fraction (TRF) (180 mg tocotrienols, 40 mg tocopherols) or placebo (0.48 mg tocotrienols, 0.88 mg tocopherols). Endpoints included measurements of inflammatory markers (C-reactive protein and interleukin 6), oxidative status (total antioxidant power and malondialdehyde), lipid profiles (plasma total cholesterol, triacylglycerols, and high-density lipoprotein cholesterol), as well as cholesteryl-ester transfer protein activity and apolipoprotein A1.
Results: TRF supplementation did not impact any nutritional, inflammatory, or oxidative status biomarkers over time when compared with the baseline within the group (one-way repeated measures analysis of variance) or when compared with the placebo group at a particular time point (independent t-test). However, the TRF supplemented group showed improvement in lipid profiles after 12 and 16 weeks of intervention when compared with placebo at the respective time points. Normalized plasma triacylglycerols (cf baseline) in the TRF group were reduced by 33 mg/dL (P=0.032) and 36 mg/dL (P=0.072) after 12 and 16 weeks of intervention but no significant improvement was seen in the placebo group. Similarly, normalized plasma high-density lipoprotein cholesterol was higher (P<0.05) in the TRF group as compared with placebo at both week 12 and week 16. The changes in the TRF group at week 12 and week 16 were associated with higher plasma apolipoprotein A1 concentration (P<0.02) and lower cholesteryl-ester transfer protein activity (P<0.001).
Conclusion: TRF supplementation improved lipid profiles in this study of maintenance hemodialysis patients. A multi-centered trial is warranted to confirm these observations.

Keyword: vitamin, tocotrienol-rich fraction, lipid profiles, hemodialysis, end-stage renal disease, nutrition intervention

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients

Mat Daud ZA, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M

Vascular Health and Risk Management 2012, 8:187-195

Published Date: 20 March 2012

Readers of this article also read:

Actual preoperative fasting time in Brazilian hospitals: the BIGFAST multicenter study

Aguilar-Nascimento JE, Almeida Dias AL, Dock-Nascimento DB, Correia MITD, Campos ACL, Portari-Filho PE, Oliveira SS

Therapeutics and Clinical Risk Management 2014, 10:107-112

Published Date: 14 February 2014

Anti-inflammatory effects of budesonide in human lung fibroblasts are independent of histone deacetylase 2

Wang X, Nelson A, Weiler ZM, Patil A, Sato T, Kanaji N, Nakanishi M, Michalski J, Farid M, Basma H, LeVan TD, Miller-Larsson A, Wieslander E, Muller KC, Holz O, Magnussen H, Rabe KF, Liu X, Rennard SI

Journal of Inflammation Research 2013, 6:109-119

Published Date: 20 August 2013

Persistent middle cerebral artery occlusion associated with lower body temperature on admission

Kvistad CE, Øygarden H, Thomassen L, Waje-Andreassen U, Naess H

Vascular Health and Risk Management 2013, 9:297-302

Published Date: 17 June 2013

Simple filter microchip for rapid separation of plasma and viruses from whole blood

Wang SQ, Sarenac D, Chen MH, Huang SH, Giguel FF, Kuritzkes DR, Demirci U

International Journal of Nanomedicine 2012, 7:5019-5028

Published Date: 17 September 2012

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Dejager S, Schweizer A, Foley JE

Vascular Health and Risk Management 2012, 8:339-348

Published Date: 18 May 2012

COSEHC global vascular risk management quality improvement program: rationale and design

Carlos M Ferrario, Michael A Moore, William Bestermann Jr, et al

Vascular Health and Risk Management 2010, 6:1135-1145

Published Date: 13 December 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis

Soniya Survase, Melanie E Ivey, Julie Nigro, Narin Osman, Peter J Little

Vascular Health and Risk Management 2005, 1:199-208

Published Date: 29 January 2005